Canaccord analyst Susan Anderson lowered the firm’s price target on Prestige Consumer (PBH) to $88 from $100 and keeps a Buy rating on the shares. The firm said they posted solid results and management noted that sales and earnings exceeded expectations due to Clear Eyes supply timing and the timing of certain retailer orders, though this will come out of 3Q now.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer Healthcare Reports Q2 Fiscal 2026 Results
- Prestige Consumer Healthcare’s Earnings Call Highlights Growth and Challenges
- Strong Performance and Positive Outlook: Buy Rating for Prestige Consumer Healthcare
- Prestige Consumer narrows FY26 adj EPS view to $4.54-$4.58 from $4.50-$4.58
- Prestige Consumer reports Q2 adjusted EPS $1.07, consensus 97c